1
|
Colafigli G, Scalzulli E, Pepe S, Di Prima A, Efficace F, Martelli M, Foà R, Breccia M. The advantages and risks of ruxolitinib for the treatment of polycythemia vera. Expert Rev Hematol 2020; 13:1067-1072. [DOI: 10.1080/17474086.2020.1816819] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Gioia Colafigli
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| | - Emilia Scalzulli
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| | - Sara Pepe
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| | - Alessio Di Prima
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| | - Fabio Efficace
- Italian Group for Adult Hematologic Diseases [GIMEMA], Health Outcomes Research Unit, Rome, Italy
| | - Maurizio Martelli
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| | - Robin Foà
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| | - Massimo Breccia
- Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1, Rome, Italy
| |
Collapse
|